Literature DB >> 10852424

Pulmonary hypertension: diagnostics and therapeutics.

M J Krowka1.   

Abstract

Pulmonary hypertension (PH) may develop because of a spectrum of insults to the lungs; in some patients, there seems to be no cause. Noninvasive tests, such as standard chest radiography, electrocardiography, and transthoracic Doppler echocardiography, provide effective screening if PH is suspected. This synopsis focuses on these screening studies and the more common clinical problems, including primary cardiac abnormalities, obstructive sleep apnea, chronic pulmonary embolism, pulmonary parenchymal problems, connective tissue disorders, cirrhosis with portal hypertension, and use of appetite suppressants, that should be considered when PH exists. Treatment options for PH, including intravenous prostacyclin (epoprostenol), and investigational agents such as subcutaneous or oral prostacyclin analogues and oral endothelin receptor antagonists are described.

Entities:  

Mesh:

Year:  2000        PMID: 10852424     DOI: 10.4065/75.6.625

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  8 in total

Review 1.  Management and follow up of prosthetic heart valves.

Authors:  Christian Seiler
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

2.  Hepatopulmonary Syndrome and Portopulmonary Hypertension.

Authors:  Michael J. Krowka
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-06

3.  Hepatopulmonary Syndrome and Portopulmonary Hypertension.

Authors:  Michael J. Krowka
Journal:  Curr Treat Options Gastroenterol       Date:  2001-12

Review 4.  Systemic hemodynamics in advanced cirrhosis: Concerns during perioperative period of liver transplantation.

Authors:  Tomohide Hori; Yasuhiro Ogura; Yasuharu Onishi; Hideya Kamei; Nobuhiko Kurata; Motoshi Kainuma; Hideo Takahashi; Shogo Suzuki; Takashi Ichikawa; Shoko Mizuno; Tadashi Aoyama; Yuki Ishida; Takahiro Hirai; Tomoko Hayashi; Kazuko Hasegawa; Hiromu Takeichi; Atsunobu Ota; Yasuhiro Kodera; Hiroyuki Sugimoto; Taku Iida; Shintaro Yagi; Kentaro Taniguchi; Shinji Uemoto
Journal:  World J Hepatol       Date:  2016-09-08

5.  Portopulmonary hypertension.

Authors:  Sarfraz Saleemi
Journal:  Ann Thorac Med       Date:  2010-01       Impact factor: 2.219

6.  cAMP-PKA-CaMKII signaling pathway is involved in aggravated cardiotoxicity during Fuzi and Beimu Combination Treatment of Experimental Pulmonary Hypertension.

Authors:  Pengwei Zhuang; Yingying Huang; Zhiqiang Lu; Zhen Yang; Liman Xu; Fengjiao Sun; Yanjun Zhang; Jinao Duan
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

7.  Protective effects of hydroalcoholic extract from rhizomes of Cynodon dactylon (L.) Pers. on compensated right heart failure in rats.

Authors:  Alireza Garjani; Arash Afrooziyan; Hossein Nazemiyeh; Moslem Najafi; Ali Kharazmkia; Nasrin Maleki-Dizaji
Journal:  BMC Complement Altern Med       Date:  2009-08-05       Impact factor: 3.659

8.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Portopulmonary hypertension.

Authors:  Sarfraz Saleemi; Majdy M Idrees
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.